Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921103 | 0.94 | MAPK1 (0.42) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9920710 | 0.90 | MAPK1 (0.40) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9920712 | 0.86 | MAPK1 (0.42) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9920898 | 0.81 | PRKAB2 (0.39) | MAPK1ALOX15ROCK2ROCK1 | |
| SCHEMBL9921095 | 0.81 | MAPK1 (0.41) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9920703 | 0.80 | PPARG (0.40) | MAPK1PPARGALOX15WDR5SSTR3 | |
| SCHEMBL9920682 | 0.79 | MAPK1 (0.42) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9920713 | 0.79 | CCNA2 (0.40) | MAPK1ALOX15 | |
| SCHEMBL9938512 | 0.79 | PPARG (0.40) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL9921100 | 0.79 | CYP2D6 (0.39) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| EP-2648511-B1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139532-B2 | Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2012078874-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | MAPK1 2483/4885HDAC3 3431/4885HDAC1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.